NCIMMUNE LEADING EARLY CANCER DETECTION

A key ingredient to Oncimmune’s success is its extensive scientific and clinical validation studies. More than 120,000 patient samples were run and 12 million data points analysed to validate the technical and clinical performance of EarlyCDTLung. Since then over 150,000 commercial tests have also been run in the US laboratory.

EarlyCDTLung is being used in the largest randomised trial for the early detection of lung cancer using biomarkers ever conducted; the National Health Service (NHS) Scotland ECLS study of 12,000 high-risk smokers.1

To see a selection of our clinical publications please go to Papers and Publications.

1 Sullivan FM, Farmer E, Mair FS et al. Detection in blood of autoantibodies to tumour antigens as case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for randomized controlled trial. BMC Cancer 2017;17:187. http://rdcu.be/pZ60

PLEASE READ THE FOLLOWING STATEMENT CAREFULLY

Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept